

Japan's Takeda Pharma provides over \$32 M for five new global CSR partnerships

20 September 2024 | News

For improving the resilience of healthcare systems in low- and middle-income countries (LMICs)



Japanese pharma firm Takeda has awarded JPY 4.6 billion (approximately \$32 million) to five new partners in the field of global corporate social responsibility (CSR). This is part of the company's ongoing commitment to improving the resilience of healthcare systems in low- and middle-income countries (LMICs) around the world.

By 2030, these new collaborations are expected to expand Takeda's impact to 27 million people in 93 countries. This brings the total contribution of Takeda's global CSR programme to over JPY 28.8 billion (approximately \$199.1 million) across 34 significant partnerships since its inception in 2016. The five new partners were selected by more than 22,000 Takeda employees in 80 countries and regions through a company-wide vote.

The new partnerships include JPY 1,007 million to Population Services International (PSI) to expand access to vaccines through pharmacy-assisted vaccinations in Ethiopia, Kenya and Nigeria; JPY 310 million for Bulungula Incubator to integrate a community-based, holistic healthcare approach into the national health system in the remote Xhorha Mouth Administrative Area in South Africa; JPY 1,169 million for Reach Out Cameroon to improve access to adequate health care and psychosocial support for women and girls in extremely hard-to-reach communities affected by long-term conflict in Cameroon, the Democratic Republic of the Congo and Nigeria; JPY 895 million to Seed Global Health to support Malawi, Sierra Leone, Uganda and Zambia in building a skilled health workforce to support national health goals; JPY 1,259 million to VillageReach to help the Democratic Republic of the Congo, Guinea, Malawi, Tanzania and Uganda strengthen the capacity of their national health systems.